Skip to content
ClinCalc Pro
Menu
H2-receptor antagonist

Cimetidine

Brand names: Tagamet

Cimetidine is a histamine H2-receptor antagonist used to reduce gastric acid secretion in conditions such as peptic ulcer disease, gastro-oesophageal reflux and dyspepsia.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It competitively blocks histamine H2 receptors on gastric parietal cells, reducing both basal and stimulated gastric acid secretion.

Prescribing in practice

  • Cimetidine is a potent inhibitor of several cytochrome P450 enzymes and raises plasma concentrations of many drugs, including warfarin, phenytoin and theophylline, so co-prescribing requires careful review and dose adjustment.
  • Doses should be reduced in renal impairment, and it can cause confusion in elderly or seriously ill patients.
  • Acid suppression may mask the symptoms of gastric cancer, so alarm features should be investigated before attributing them to benign dyspepsia.

Monitoring

Routine laboratory monitoring is not required, but monitor the effects of interacting drugs, such as the INR in patients taking warfarin, and review renal function where relevant.

Counselling the patient

  • Tell your prescriber about all your other medicines, as interactions are common.
  • Report any persistent difficulty swallowing, weight loss or signs of bleeding.
  • Let your team know if you feel confused, particularly if you are elderly or unwell.

Evidence & guidelines

H2-receptor antagonists are an established acid-suppressing option for peptic ulcer disease and reflux, though proton pump inhibitors are generally preferred first-line in NICE guidance.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.